Drug Combination Details

General Information of the Combination (ID: C07068)
Name Miltefosine   NP Info  + Paromomycin   Drug Info 
Structure +
Disease
Leishmaniasis [ICD-11: 1F54]
Phase 3 [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Molecule(s)
                    Regulation		 Up-regulation Expression p105  Molecule Info 
Pathway MAP
Up-regulation Expression TNF  Molecule Info 
Pathway MAP
                    In-vitro Model HEK293 CVCL_0045 Healthy Homo sapiens
                    Experimental
                    Result(s)		 The in vitro activity of paromomycin and miltefosine against host cells is TLR4 dependent.
References
Reference 1 ClinicalTrials.gov (NCT03829917) Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis.
Reference 2 Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro. J Antimicrob Chemother. 2012 Oct;67(10):2373-8.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link